Two Sigma Advisers’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-155,600
| Closed | -$1.41M | – | 2126 |
|
|
2025
Q4 | $1.41M | Sell |
155,600
-160,000
| -51% | -$1.2M | ﹤0.01% | 1323 |
|
|
2025
Q3 | $982K | Buy |
315,600
+143,200
| +83% | +$379K | ﹤0.01% | 1471 |
|
|
2025
Q2 | $369K | Sell |
172,400
-24,129
| -12% | -$39K | ﹤0.01% | 1878 |
|
|
2025
Q1 | $226K | Sell |
196,529
-604,271
| -75% | -$1.04M | ﹤0.01% | 2097 |
|
|
2024
Q4 | $1.75M | Buy |
800,800
+335,400
| +72% | +$760K | ﹤0.01% | 1183 |
|
|
2024
Q3 | $1.01M | Buy |
465,400
+252,400
| +118% | +$580K | ﹤0.01% | 1406 |
|
|
2024
Q2 | $492K | Buy |
213,000
+124,600
| +141% | +$518K | ﹤0.01% | 1888 |
|
|
2024
Q1 | $486K | Sell |
88,400
-1,020,700
| -92% | -$4.67M | ﹤0.01% | 1884 |
|
|
2023
Q4 | $2.74M | Buy |
+1,109,100
| New | +$10.5M | 0.01% | 1112 |
|
|
2023
Q3 | – | Sell |
-8,200
| Closed | -$269K | – | 2589 |
|
|
2023
Q2 | $269K | Buy |
+8,200
| New | +$283K | ﹤0.01% | 2015 |
|
|
2023
Q1 | – | Sell |
-30,000
| Closed | -$984K | – | 2765 |
|
|
2022
Q4 | $984K | Buy |
30,000
+22,000
| +275% | +$652K | ﹤0.01% | 1574 |
|
|
2022
Q3 | $279K | Buy |
+8,000
| New | +$177K | ﹤0.01% | 2069 |
|
Other funds holding VTYX
Two Sigma Advisers's VTYX Position: Q1 2026 in Review
Two Sigma Advisers sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 155,600 shares — an estimated $1.41M sold.
Two Sigma Advisers first reported a position in VTYX in Q3 2022 and held it in 12 quarters. The position peaked at $2.74M in Q4 2023. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Two Sigma Advisers reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 155,600 Ventyx Biosciences shares in Q1 2026, an estimated $1.41M.
- Two Sigma Advisers first reported a position in Ventyx Biosciences in Q3 2022 and held it in 12 quarters.
- Two Sigma Advisers's Ventyx Biosciences position peaked at $2.74M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.